Henan Lingrui Pharmaceutical Co Ltd
SSE:600285

Watchlist Manager
Henan Lingrui Pharmaceutical Co Ltd Logo
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Watchlist
Price: 22.17 CNY -3.06%
Market Cap: 12.6B CNY
Have any thoughts about
Henan Lingrui Pharmaceutical Co Ltd?
Write Note
Section:
 
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Henan Lingrui Pharmaceutical Co Ltd

Wall Street analysts forecast Henan Lingrui Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Henan Lingrui Pharmaceutical Co Ltd is 30.65 CNY with a low forecast of 29.9 CNY and a high forecast of 32.03 CNY.

Lowest Forecast
Wall Street Target
29.9 CNY
35% Upside
Average Forecast
Wall Street Target
30.65 CNY
38% Upside
Highest Forecast
Wall Street Target
32.03 CNY
44% Upside
Lowest
Price Target
29.9 CNY
35% Upside
Average
Price Target
30.65 CNY
38% Upside
Highest
Price Target
32.03 CNY
44% Upside
Henan Lingrui Pharmaceutical Co Ltd Competitors:
Price Targets
AMLX
Amylyx Pharmaceuticals Inc
100% Upside
2096
Simcere Pharmaceutical Group Ltd
40% Upside
DMP
Dermapharm Holding SE
29% Upside
ZTS
Zoetis Inc
35% Upside
AMLX
Amylyx Pharmaceuticals Inc
100% Upside
2096
Simcere Pharmaceutical Group Ltd
40% Upside
DMP
Dermapharm Holding SE
29% Upside
ZTS
Zoetis Inc
35% Upside
INVA
Innoviva Inc
9% Upside
MARKSANS
Marksans Pharma Ltd
7% Upside
NEU
Neuren Pharmaceuticals Ltd
131% Upside
128940
Hanmi Pharm Co Ltd
59% Upside

Revenue
Forecast

Revenue Estimate
Henan Lingrui Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Henan Lingrui Pharmaceutical Co Ltd's revenue is 15%. The projected CAGR for the next 3 years is 13%.

15%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Henan Lingrui Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Henan Lingrui Pharmaceutical Co Ltd's operating income is 21%. The projected CAGR for the next 3 years is 20%.

21%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Henan Lingrui Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Henan Lingrui Pharmaceutical Co Ltd's net income is 20%. The projected CAGR for the next 3 years is 20%.

20%
Past Growth
20%
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Henan Lingrui Pharmaceutical Co Ltd's stock price target?
Price Target
30.65 CNY

According to Wall Street analysts, the average 1-year price target for Henan Lingrui Pharmaceutical Co Ltd is 30.65 CNY with a low forecast of 29.9 CNY and a high forecast of 32.03 CNY.

What is Henan Lingrui Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
13%

For the last 8 years the compound annual growth rate for Henan Lingrui Pharmaceutical Co Ltd's revenue is 15%. The projected CAGR for the next 3 years is 13%.

What is Henan Lingrui Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Henan Lingrui Pharmaceutical Co Ltd's operating income is 21%. The projected CAGR for the next 3 years is 20%.

What is Henan Lingrui Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Henan Lingrui Pharmaceutical Co Ltd's net income is 20%. The projected CAGR for the next 3 years is 20%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.